Global molecular diagnostics company Genetic Signatures (ASX: GSS) has decided to halt the development of its EasyScreen Essentials Respiratory Detection Kit for the US market due to increased competition and changing market dynamics. It will now focus its effort and investment on the anticipated launch of the EasyScreen Gastrointestinal Parasite Detection Kit in the US.
Read More
A recent report revealed that, in the US, the rate of babies being born prematurely has been rising. Between 2014 and 2022, premature births grew 12% to 8.7%. This paints a concerning picture for mothers and infants who face great risk. To address this, point-of-care diagnostic technologies Lumos Diagnostics (ASX: LDX) has been working on
Read More
Molecular diagnostics company Genetic Technologies (ASX: GTG) is piloting its risk assessment test geneType in breast screening centres across the US. The Company is establishing a clinical implementation study with breast imaging centres in New York, Miami and Houston. In the US, screening is currently between the ages of 40 and 74. So, the current
Read More
Aussie biosensor company Universal Biosensors (ASX: UBI) has received the US FDA 510(k) and CLIA Waiver approval for its Xprecia Prime Coagulation Analyzer as a Class II device. Xprecia Prime is a portable coagulation monitoring device that provides fast and accurate PT/INR testing (measuring how long it takes for blood to clot) specifically for patients
Read More
Australia’s labour shortage struggles are far from over, continuing to impact companies like diagnostic imaging services provider Integral Diagnostics (ASX: IDX). This impact was reflected in its mixed results for the first half of FY24. Integral Diagnostics is an Australia and New Zealand-based medical diagnostics company offering radiology services—from X-rays and CT scans to ultrasounds,
Read More
Aussie medical device company Atomo Diagnostics (ASX: AT1), which provides rapid diagnostic tests, witnessed strong growth in revenue and margins across its business ventures, especially its HIV Self-Test business. Thanks to improved awareness and accessibility, the self-test sold over 130,000 units in Q2 FY24, ending December 2023. The sales were primarily in high-value developed markets
Read More